Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) Shares outstanding
Regeneron Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $108.6M, down 5.65% from $115.1M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $106.0M. Over the past ten years it has ranged from $108.6M (fiscal 2025) to $116.3M (fiscal 2016) — the current reading is the lowest in ten years. Regeneron Pharmaceuticals, Inc. ranks 137th of 604 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $108.6M | (5.65%) |
| FY2024 | $115.1M | 1.23% |
| FY2023 | $113.7M | 0.18% |
| FY2022 | $113.5M | 1.16% |
| FY2021 | $112.2M | (2.52%) |
| FY2020 | $115.1M | 0.44% |
| FY2019 | $114.6M | (0.17%) |
| FY2018 | $114.8M | (0.95%) |
| FY2017 | $115.9M | (0.34%) |
| FY2016 | $116.3M | 0.93% |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $106.0M | (1.58%) |
| Mar 2026 | $107.7M | (0.83%) |
| Dec 2025 | $108.6M | 1.31% |
| Sep 2025 | $107.2M | (1.29%) |
| 42 more quarters | Free account |
Against its own ten years
Low $108.6M
High $116.3M
Ten-year median
$114.8M
Current reading's percentile
9
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RPRX Royalty Pharma PLC compare | $556.9M |
| MRNA Moderna, Inc. compare | $398.0M |
| VRTX Vertex Pharmaceuticals Incorporated compare | $255.2M |
| INSM Insmed, Inc. compare | $217.4M |
| RVMD Revolution Medicines, Inc. compare | $210.9M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.3M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| REGN Regeneron Pharmaceuticals, Inc. | $106.0M |
| ARGX argenex SE compare | $64.5M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on REGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement